Are you searching for a new strategy to give your investments a crunchy uplift? The answer may be found in two favourite breakfast cereals.
This list of businesses compiled earlier this year by the US investment bank Goldman Sachs, actually spells out 'Grannnollass'. This new acronym, devised by Paras Anand, chief investment officer of Artemis, is based on an analysis that identifies companies with the most attractive fundamentals, at the best prices.
Among the Granolas are the British giants: AstraZeneca, the £216billion group which boasts 13 major drugs such as the chemotherapy treatment Enhertu. For the moment, Novo Nordisk of Denmark dominates the weight loss game with its injectables Ozempic and Wegovy. It now faces more competition from Eli Lilly's obesity blockbuster Mounjaro. But its shares, which stand at 912 krone , are still rated a 'buy'.
TECHNOLOGYASML, the Dutch group, which makes equipment for microchips production is regarded as Europe's 'stand-out AI winner'. Which is why its shares are more than 1,000 per cent up on a decade ago. Indra Sistemas, a Spanish group, supplies IT services to the air traffic management, defence and transport industries.
Analysts rate the shares a hold, although they are still targeting a 100 Swiss franc price and hoping that new boss Laurent Freixe will reverse the slide.